It is our pride privilege and great honor to guest edit this thematic issue of the Journal of Postgraduate Medicine Education and Research (JPMER). All of us decided to take 'Receptor-targeted Molecular Imaging and Radionuclide Therapy: A Path to personalized Medicine' as the theme of this issue of JPMER.
Since, the first World Congress on ' 68 Ga Molecular Imaging and Radionuclide Therapy' organized under the stewardship of Prof Richard P Baum (June, 2011, Bad Berka, Germany), we have continued to witness the proliferation of new 68 Ga-labeled compounds for molecular imaging of cancer. Much as early discoveries of differences in cancer cell metabolism led to the development of small molecule imaging agents (e.g. Ga are founded on discoveries that identify fundamental differences in tumor cell extracellular antigen expression, relative nonmalignant cells. These discoveries are the foundation for the next generation of molecular targets for selective delivery of radiation dose to tumor cells for diagnosis, monitoring and selecting patients that can benefit most from receptor-targeted radionuclide therapies. Thus, our efforts in this area have the potential to advance molecular imaging science toward personalized medicine.
In the second World Congress (SWC-2013) organized (28th Feb-2nd March, 2013) by the Department of Nuclear Medicine and PET at the Postgraduate Institute for Medical Education and Research (Chandigarh, India), leading scientists and physicians in 68 Ga-based molecular imaging and peptide receptor-targeted radionuclide therapy gathered to share their latest discoveries and technical developments that are shaping the future for this field. New applications for 68 Ga are highlighted and the latest developments in generator technologies as well as new directions for targeted radionuclide therapy are presented. The scientific deliberations of the SWC-2013 (attended by more than 500 Experts/Delegates from over 30 countries) promised a brighter future for these modalities of imaging and therapy as we discover new molecular targets that are enabling us to selectively target cancer cells. The challenge, as we move forward, is to combine our advances in radionuclide technologies with new discoveries of molecular target expression in cancer cells for more precise delivery of therapies. In this way, we move forward toward a personalized approach to molecular diagnostics and targeted therapies.
The compilation of the presentations and discussions as original and review articles in this Congress dedicated thematic issue of JPMER provides a very comprehensive document for those practicing 'Receptor Targeted Molecular Imaging and Radionuclide therapy' with the common aim of achieving the goal of providing personalized medicine to the patients.
We sincerely thank all the authors for contributing exceptionally high quality scientific original and review articles. The guest editors also thank the JPMER editorial team (PGIMER, Chandigarh, India) for entrusting us with the task of bringing out this thematic issue of the journal.
